摘要
目的:观察乌司他丁联合奥曲肽治疗重症急性胰腺炎的效果。方法:选取105例重症急性胰腺炎患者作为研究对象,根据治疗方法将其分为对照组50例和观察组55例。对照组给予奥曲肽治疗,观察组在对照组的基础上给予乌司他丁治疗。比较两组临床疗效、治疗前后血液流变学指标水平及并发症发生情况。结果:观察组治疗有效率为90.91%(50/55),高于对照组的76.00%(38/50),差异有统计学意义(P<0.05);治疗前两组低切血黏度、高切血黏度及血浆黏度水平比较,差异无统计学意义(P>0.05);治疗后两组低切血黏度、高切血黏度及血浆黏度水平均明显低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组并发症发生率为1.82%,明显低于对照组的12.00%,差异有统计学意义(P<0.05);疗前两组血清淀粉酶和尿淀粉酶水平比较,差异无统计学意义(P>0.05);治疗后,两组血清淀粉酶和尿淀粉酶水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论:与单用奥曲肽治疗相比,乌司他丁联合奥曲肽治疗重症急性胰腺炎的效果更显著,可有效改善患者血液流变学指标水平,降低血清淀粉酶和尿淀粉酶水平,不良反应少。
Objective: To observe effects of Ulinastatin combined with Octreotide on severe acute pancreatitis. Methods: A total of 105 patients with severe acute pancreatitis were enrolled as the subjects. They were divided into control group(n=50) and observation group(n=55) according to the treatment methods. The control group received Octreotide treatment, while the observation group received Ulinastatin combined with Octreotide. The clinical effects, hemorheologic parameter levels and complication rates were compared between the two groups. Results: The effective rate in the observation group was 90.91%(50/55), which was higher than 76.00%(38/50) in the control group, and the difference was statistically significant(P<0.05). There were no significant differences in the blood viscosity at low and high shear rates as well as the plasma viscosity between the two groups before the treatment(P>0.05). However, after the treatment, the blood viscosity at low and high shear rates as well as the plasma viscosity of the two group were significantly lower than those before the treatment, those of the observation group were lower than those of the control group, and the differences were statistically significant(P<0.05). The incidence of complications in the observation group was 1.82%, which was significantly lower than 12.00% in the control group, and the difference was statistically significant(P<0.05). There were no significant differences in the blood and urine amylase levels between the two groups before the treatment(P>0.05). However, after the treatment, the blood and urine amylase levels in the two groups were lower than those before the treatment, those of the observation group were lower than those of the control group, and the differences were statistically significant(P<0.05). Conclusions: Compared with Octreotide alone, Ulinastatin combined with Octreotide in the treatment of severe acute pancreatitis is more significantly effective. It can effectively improve the hemorheology parameters of these patients and reduce the hematuria amylase levels with fewer adverse reactions.
作者
宋微
SONG Wei(Huludao Central Hospital,Huludao 125000 Liaoning,China)
出处
《中国民康医学》
2019年第22期17-19,共3页
Medical Journal of Chinese People’s Health
关键词
重症急性胰腺炎
乌司他丁
奥曲肽
血液流变学
Severe acute pancreatitis
Ulinastatin
Octreotide
Hemorheology
Effect
作者简介
宋微(1983.08-),女,汉族,辽宁省葫芦岛市人,本科,主治医师,研究方向:消化内科,邮箱:779560@qq.com。
